Literature DB >> 16818283

Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia.

Nasios Fourouclas1, Peter J Campbell, Anthony J Bench, Soheila Swanton, E Joanna Baxter, Brian Jp Huntly, Anthony R Green.   

Abstract

Deletions of the derivative 9 chromosome (der(9)) are associated with poor prognosis in chronic myeloid leukemia (CML). Several models have been proposed to account for this association. To distinguish between the various models we mapped the deletion in 69 Philadelphia-positive CML patients carrying a der(9) deletion and compared the size of the deletion with the patients' outcome. Our results demonstrate that patients with large deletions had a significantly worse survival than those with small deletions whereas the outcome for patients with small deletions was similar to that of patients lacking a deletion. These results support the tumor suppressor gene model for the pathogenesis of der(9) deletions, argue against alternative models and provide insight into candidate gene location.

Entities:  

Mesh:

Year:  2006        PMID: 16818283

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  7 in total

1.  Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.

Authors:  Lina Shao; Sung-Hae L Kang; Jian Li; Patricia Hixson; Jesalyn Taylor; Svetlana A Yatsenko; Chad A Shaw; Aleksandar Milosavljevic; Chung-Che Chang; Sau Wai Cheung; Ankita Patel
Journal:  J Mol Diagn       Date:  2010-08-19       Impact factor: 5.568

2.  Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients.

Authors:  Ayda Bennour; Hatem Bellâaj; Yosra Ben Youssef; Moez Elloumi; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-08       Impact factor: 4.553

3.  Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.

Authors:  Ayda Bennour; Ines Ouahchi; Yosra Ben Youssef; Monia Zaier; Mohamed Adnéne Laatiri; Imed Harrabi; Balkis Meddeb; Moez Elloumi; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Med Oncol       Date:  2011-04-03       Impact factor: 3.064

4.  Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): An Update.

Authors:  Heyang Zhang; Meng Liu; Xiaoxue Wang; Yuan Ren; Young Mi Kim; Xianfu Wang; Xianglan Lu; Hui Pang; Guangming Liu; Yue Gu; Mingran Sun; Yunpeng Shi; Chuan Zhang; Yaowen Zhang; Jianqin Zhang; Shibo Li; Lijun Zhang
Journal:  Front Genet       Date:  2021-08-10       Impact factor: 4.599

5.  Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.

Authors:  Carmino Antonio de Souza; Katia Borgia Barbosa Pagnano; Israel Bendit; Monika Conchon; Carla Maria Boquimpani de Moura Freitas; Arthur Moellmann Coelho; Vaneuza Araújo Moreira Funke; Wanderley Marques Bernardo
Journal:  Rev Bras Hematol Hemoter       Date:  2012

6.  Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jianqin Shan; Elias Jabbour; Lynne V Abruzzo; Srdan Verstovsek; Guillermo Garcia-Manero; Susan O'Brien; Jorge Cortes
Journal:  Cancer       Date:  2011-04-26       Impact factor: 6.860

7.  SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

Authors:  Daniel Nowak; Seishi Ogawa; Markus Müschen; Motohiro Kato; Norihiko Kawamata; Antonie Meixel; Verena Nowak; Han S Kim; Sharon Kang; Ronald Paquette; Mi-Sook Chang; Nils H Thoennissen; Nils H Thoenissen; Max Mossner; Wolf-Karsten Hofmann; Alexander Kohlmann; Tamara Weiss; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Journal:  Blood       Date:  2009-12-02       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.